Applied Therapeutics

OverviewSuggest Edit

Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) that is being developed for the treatment of diabetic cardiomyopathy, or DbCM, fatal fibrosis of the heart. The company is also developing AT-007, a central nervous system penetrant ARI, for the treatment of galactosemia.

TypePublic
Founded2017
HQNew York, NY, US
Websiteappliedtherapeutics.com

Latest Updates

Employees (est.) (Dec 2019)11(+10%)
Share Price (Apr 2021)$18.2(-2%)
Cybersecurity ratingAMore

Key People/Management at Applied Therapeutics

Shoshana Shendelman

Shoshana Shendelman

CEO & Founder
Riccardo Perfetti

Riccardo Perfetti

Chief Medical Officer
Charles Silberstein

Charles Silberstein

Chief Financial Officer
Adam Hansard

Adam Hansard

Chief Commercial Officer
Show more

Applied Therapeutics Office Locations

Applied Therapeutics has an office in New York
New York, NY, US (HQ)
545 5th Ave #1400
Show all (1)

Applied Therapeutics Financials and Metrics

Applied Therapeutics Revenue

USD

Net income (FY, 2020)

(94.0m)

EBIT (FY, 2020)

(94.5m)

Market capitalization (1-Apr-2021)

473.6m

Closing stock price (1-Apr-2021)

18.2

Cash (31-Dec-2020)

57.5m

EV

417.9m
Applied Therapeutics's current market capitalization is $473.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

582.0k2.0m13.2m32.7m

R&D expense

3.7m11.5m32.4m61.8m

Operating expense total

4.3m13.5m45.6m94.5m

EBIT

(4.3m)(13.5m)(45.6m)(94.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.9m4.2m3.3m5.2m7.5m

R&D expense

6.9m4.3m7.5m7.3m20.8m

Operating expense total

8.7m8.4m10.7m12.5m28.3m

EBIT

(8.7m)(8.4m)(10.7m)(12.5m)(28.3m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.3m18.7m18.9m57.5m

Prepaid Expenses

9.0k1.5m7.3m5.8m

Current Assets

3.3m20.2m46.2m102.6m

Total Assets

3.3m20.2m48.4m104.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

14.7m41.1m13.1m92.5m100.9m

Prepaid Expenses

2.2m5.7m4.1m9.4m10.0m

Current Assets

16.9m46.8m37.0m163.7m148.5m

Total Assets

16.9m46.8m37.3m165.9m150.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.3m)(16.5m)(45.5m)(94.0m)

Accounts Payable

5.8m(8.0m)

Cash From Operating Activities

(3.2m)(11.2m)(36.3m)(78.2m)

Cash From Investing Activities

(20.0m)(19.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(8.7m)(17.2m)(27.9m)(12.4m)(40.4m)

Accounts Payable

(366.0k)462.0k(1.3m)(7.2m)(3.1m)

Cash From Operating Activities

(7.0m)(16.1m)(23.9m)(18.9m)(34.8m)

Cash From Investing Activities

(19.9m)(41.7m)(17.7m)
USDFY, 2017

Financial Leverage

1.4 x
Show all financial metrics

Applied Therapeutics Operating Metrics

Q1, 2019

Phase II Patients Enrolled

120
Show all operating metrics

Applied Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Applied Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Applied Therapeutics Online and Social Media Presence

Embed Graph

Applied Therapeutics News and Updates

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at …

Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA

Applied Therapeutics to Host Virtual Rare Disease Forum

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Ra…

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at tw…

Applied Therapeutics, Inc. Announces Closing of Public Offering

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the closin…

Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it pl…
Show more

Applied Therapeutics Blogs

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

Applied Therapeutics to be Added to NASDAQ Biotechnology Index Content Import Tue, 12/15/2020 - 08:00 Applied Therapeutics to be Added to NASDAQ Biotechnology Index Dec 15, 2020 This release is a backfill from a News Wire General NEW…

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Applied Therapeutics Reports Third Quarter 2020 Financial Results Content Import Thu, 11/12/2020 - 07:01 Applied Therapeutics Reports Third Quarter 2020 Financial Results November 12, 2020 at 7:00 AM EST This release is a backfill from a News Wire …

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020 Content Import Mon, 11/09/2020 - 07:03 Applied Therapeutics Announces Presentation of Pre-Clinical Data o…

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

NEW YORK , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

NEW YORK , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S.

Applied Therapeutics to Present at Citi and Baird Investor Conferences

NEW YORK , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at
Show more

Applied Therapeutics Frequently Asked Questions

  • When was Applied Therapeutics founded?

    Applied Therapeutics was founded in 2017.

  • Who are Applied Therapeutics key executives?

    Applied Therapeutics's key executives are Shoshana Shendelman, Riccardo Perfetti and Charles Silberstein.

  • How many employees does Applied Therapeutics have?

    Applied Therapeutics has 11 employees.

  • Who are Applied Therapeutics competitors?

    Competitors of Applied Therapeutics include Auxulin Pharmaceuticals, Abarceo Pharma and Amarillo Biosciences.

  • Where is Applied Therapeutics headquarters?

    Applied Therapeutics headquarters is located at 545 5th Ave #1400, New York.

  • Where are Applied Therapeutics offices?

    Applied Therapeutics has an office in New York.

  • How many offices does Applied Therapeutics have?

    Applied Therapeutics has 1 office.